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Abstract
Background:  Pulmonary surfactant reduces surface tension and is present at the air-liquid
interface in the alveoli where inhaled nanoparticles preferentially deposit. We investigated the
effect of titanium dioxide (TiO2) nanosized particles (NSP) and microsized particles (MSP) on
biophysical surfactant function after direct particle contact and after surface area cycling in vitro. In
addition, TiO2 effects on surfactant ultrastructure were visualized.
Methods: A natural porcine surfactant preparation was incubated with increasing concentrations
(50-500 μg/ml) of TiO2 NSP or MSP, respectively. Biophysical surfactant function was measured in
a pulsating bubble surfactometer before and after surface area cycling. Furthermore, surfactant
ultrastructure was evaluated with a transmission electron microscope.
Results: TiO2 NSP, but not MSP, induced a surfactant dysfunction. For TiO2 NSP, adsorption
surface tension (γads) increased in a dose-dependent manner from 28.2 ± 2.3 mN/m to 33.2 ± 2.3
mN/m (p < 0.01), and surface tension at minimum bubble size (γmin) slightly increased from 4.8 ±
0.5 mN/m up to 8.4 ± 1.3 mN/m (p < 0.01) at high TiO2 NSP concentrations. Presence of NSP
during surface area cycling caused large and significant increases in both γads (63.6 ± 0.4 mN/m) and
γmin (21.1 ± 0.4 mN/m). Interestingly, TiO2 NSP induced aberrations in the surfactant ultrastructure.
Lamellar body like structures were deformed and decreased in size. In addition, unilamellar vesicles
were formed. Particle aggregates were found between single lamellae.
Conclusion:  TiO2  nanosized particles can alter the structure and function of pulmonary
surfactant. Particle size and surface area respectively play a critical role for the biophysical
surfactant response in the lung.
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Background
High amounts of ambient particulate matter (PM) exist in
our atmosphere, and it is known that a high proportion of
these particles are nanosized particles (NSP) with a diam-
eter of ≤ 100 nm. NSP can be found in the air as a result
of combustion processes such as automobile engines and
fires. In addition, the rapidly developing field of nanote-
chnology is becoming a potential source for human expo-
sure to NSP. Titanium dioxide (TiO2) NSP e.g. are widely
produced for industrial processes since several years [1].
Importantly, PM exposure is linked with the occurrence of
cardio-respiratory disease as well as mortality [2,3]. Epide-
miological and experimental data suggest a relationship
between PM and e.g. asthma [4], chronic obstructive pul-
monary disease [5], and cystic fibrosis [6,7]. Unfortu-
nately, the exact mechanism by which PM induces or
aggravates airway disease is still unknown.
Dependent on their size, particles preferentially deposit in
different compartments of the lung. Importantly, most of
the nanosized particles have a high alveolar deposition
rate [8]. In the alveoli, these particles come into contact
with the pulmonary surfactant layer that covers the entire
alveolar region. Surfactant decreases the surface tension at
the air-liquid interface and thereby prevents alveolar col-
lapse. Surface activity is mainly accomplished by sur-
factant phospholipids and the specific surfactant proteins
(SP)-B, and -C. Morphologically, surfactant exists in dif-
ferent subfractions. The surface active fraction consists of
lamellar bodies and tubular myelin whereas the less sur-
face active fraction is comprised of unilamellar vesicles. By
ultracentrifugation, lamellar bodies and tubular myelin
can be pelleted and are thereby called large aggregates
(LA). In contrast, unilamellar vesicles remain in the super-
natant and are defined as small aggregates (SA). Conver-
sion of LA into SA occurs during respiration [9].
It has been demonstrated that particles of anthropogenic
origin are able to directly interact with pulmonary sur-
factant components [10-13]. Further, it has been shown
that nanosized particles can disturb surfactant function
[14,15]. However, a systematic comparison of nanosized
and microsized particles (MSP) of different composition
has not been made. Moreover, it is unclear whether parti-
cle-surfactant interactions during dynamic conditions of
surface area cycling aggravate the biophysical surfactant
dysfunction. Therefore, we investigated the effect of
increasing concentrations of TiO2 NSP and TiO2 MSP, as
model particles, on pulmonary surfactant function by
means of a pulsating bubble surfactometer both under
native conditions and following surface area cycling. For
comparison reasons, the effect on surfactant function was
investigated for nanosized and microsized polystyrene
particles as well as for quartz particles. Furthermore, we
studied the effect of nanosized TiO2particles on surfactant
ultrastructure by transmission electron microscope
(TEM). In order to elaborate on the in-vivo relevance, rats
were exposed to TiO2 NSP versus TiO2 MSP, lungs were
fixed and lung tissue blocks were prepared for electron
microscopy. The ultrastructure and distribution of the dif-
ferent subtypes of intra-alveolar surfactant was observed.
Methods
Particles
Nanosized and microsized titanium dioxide particles
(Alfa Aesar, Karlsruhe, Germany; product numbers:
44689 & 42681) were used in this study. For comparison,
polystyrene particles (Micromod, Rostock-Warnemuende,
Germany), Sikron SF 800 quartz particles (Quarzwerke,
Frechen, Germany) as well as citrate coated nanosized
gold particles (Plano, Wetzlar Germany: product number:
EM.GC5) were studied [for details see additional file 1].
Particle stock solutions were prepared in sterilized bidis-
tilled water at a concentration of 25 mg/ml or 50 mg/ml.
Particles were sonicated prior to each experiment.
Acute Effects on Biophysical Surfactant Function
A natural porcine surfactant preparation (Curosurf®,
Asche Chiesi, Hamburg, Germany) was used as a standard
and was adjusted to 1.5 mg/ml phospholipids in Ringer's
solution. Particles at increasing concentrations were
added (50 μg/ml - 500 μg/ml) and biophysical surfactant
function was assessed with a pulsating bubble surfactom-
eter (PBS) (Electronetics, Buffalo, NY, USA) as described
below.
Surface Area Cycling
Surface area cycling is a standardized method to simulate
the in vivo conversion of surface active surfactant subtypes
(lamellar bodies, tubular myelin) to inferior surfactant
subtypes (unilamellar vesicles) in vitro [16-20]. We meas-
ured the biophysical surfactant function following surface
area cycling in the presence or absence of particles in order
to assess the effect of particles during the conversion proc-
ess. Curosurf® was adjusted to 1.5 mg/ml phospholipids
in ringer solution with or without particles in increasing
concentrations (50 μg/ml - 500 μg/ml). Aliquots were
placed in 12 × 75 mm capped plastic tubes (Falcon 2058)
and rotated end over end for 8 hours at 0.43 Hz and 37°C
in the dark. Thereby, surface area changed from 1.1 cm2 to
9 cm2 twice per cycle. After surface area cycling biophysi-
cal surfactant function was measured in a pulsating bub-
ble surfactometer as described below.
Surface Activity Evaluated with the Pulsating Bubble 
Surfactometer
Surface activity of pulmonary surfactant was measured
with a PBS. Forty μl of the surfactant mixture were filled
into the sample chamber. The surface tension used for sta-Respiratory Research 2009, 10:90 http://respiratory-research.com/content/10/1/90
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tistical analysis of this study was the value at minimum
bubble size (γmin) registered after 330 seconds of pulsa-
tion at a rate of 20 cycles/min and a temperature of 37°C.
In addition, adsorption surface tension (γads) was evalu-
ated by determining surface tension 10 s after formation
of a bubble under static bubble conditions. All data were
digitalized and recorded by computer. All assays were per-
formed in duplicate and the mean value was reported. The
PBS was calibrated and checked with reference substances
for proper operation before starting the measurements on
each day.
Transmission Electron Microscope
Surfactant was fixed in Eppendorf tubes with 1.5% glutar-
aldehyde and 1.5% paraformaldehyde in 0.15 M Hepes
buffer. The samples were stored in the fixative for 1 hour
at room temperature and at least 24 hours at 4°C. After-
wards, samples were centrifuged at 10,000 g to obtain a
surfactant pellet. After several washings in buffer, the sam-
ples were subsequently postfixed in osmium tetroxide and
half-saturated aqueous uranyl acetate, dehydrated in an
ascending acetone series and embedded in Epon at 60°C.
The Eppendorf cups were removed and ultrathin 50 nm
sections were cut using an ultramicrotome. The sections
were analyzed with a Philips CM12 transmission electron
microscope (FEI Co. Philips Electron Optics, Zürich, Swit-
zerland).
Exposure of rats to particles and assessment of surfactant 
ultrastructure
Female Wistar rats (162 - 200 g) were randomly exposed
once for 6 hours to either TiO2 NSP (P25; Evonik Degussa,
Essen, Germany), TiO2  MSP (Bayertitan T, Bayer,
Leverkusen, Germany), or clean air, respectively (n = 5 per
group). The exposure atmosphere was adjusted to either
10 mg TiO2 MSP/m3 or 25 mg TiO2 NSP/Na2HPO4/m3
(60% Na2HPO4; 40% TiO2 NSP). Since the TiO2 MSP and
TiO2  NSP/Na2HPO4  droplets in the atmosphere were
approximately of the same size, a similar alveolar deposi-
tion rate of 60 μg TiO2 particles per animal was accom-
plished [21]. Rats were sacrificed by pentobarbital
overdose at the end of the exposure and the lungs were
perfusion-fixated as described before [22]. Surfactant
ultrastructure was assessed on ultrathin sections by elec-
tron microscopy and surfactant subtype conversion was
studied semiquantitatively.
Statistical Analysis
Values are given as means ± SEM. Statistical analysis was
performed using GraphPad Prism®, Version 4.03. The one-
way ANOVA was used for statistical analysis of the data. A
Bonferroni correction was used throughout. P values <
0.05 were considered to be significant.
Results
Direct Effect of Particles on Pulmonary Surfactant 
Function
To assess the direct effect of particles on surfactant func-
tion, surface tension was measured after addition of parti-
cles. Pure surfactant showed an adsorption surface tension
of ~28 mN/m and addition of TiO2 NSP in concentrations
up to 200 μg/ml did not affect this active surface tension
(Figure 1A). However, further increase of the particle dose
up to 500 μg/ml led to a significant increase in adsorption
surface tension to 33.2 ± 2.3 mN/m. In contrast, surface
tension was unaffected by treatment with the same mass
concentrations of TiO2 MSP (Figure 1B). TiO2 NSP slightly
increased γmin from ≤ 5 mN/m, which denotes active sur-
factant, up to 8.4 ± 1.3 mN/m at 500 μg/ml (Figure 1C).
Again, TiO2 MSP showed no effect on surface tension in
this concentration range (Figure 1D). However, at very
high particle concentrations of TiO2 MSP (~10 mg/ml)
that deliver a similar surface area compared to TiO2 NSP
γmin increased to 15.9 ± 1.3 mN/m (n = 6, p < 0.01).
As for the TiO2 particles similar results were observed for
the other particles. Whereas polystyrene NSP significantly
increased adsorption surface tension for 500 μg/ml, poly-
styrene and quartz MSP did not influence the surface ten-
sion up to a concentration of 500 μg/ml (Table 1). In
addition, nanosized polystyrene particles increased sur-
face tension at minimum bubble size significantly at 500
μg/ml up to 6.8 ± 1.2 mN/m, whereas microsized particles
did not influence surfactant function in this concentration
range (Table 1). Again, MSP (Quartz) at a very high con-
centration (~10 mg/ml) that deliver a similar surface area
compared to TiO2 NSP increased γmin to 15.5 ± 1.8 mN/m
(n = 5, p < 0.05).
Furthermore, we tested commercially available gold NSP
with citrate coating (5 nm) in single experiments. At 200
μg/ml and 500 μg/ml, gold NSP increased γmin to 7.7 ± 2.8
and 13.2 ± 5.3, respectively (n = 4).
Effects of Particles Following Surface Area Cycling
Surface area cycling alone led to an increase in adsorption
surface tension from ~28 to ~45 mN/m (Figure 2A and
2B). The presence of TiO2 NSP in concentrations of 200
μg/ml and 500 μg/ml during the cycling process led to a
further increase of adsorption surface tension to 53.3 ±
1.3 mN/m and 63.6 ± 0.4 mN/m, respectively (Figure 2A).
TiO2 MSP concentrations up to 500 μg/ml did not affect
adsorption surface tension (Figure 2B). The influence of
TiO2 NSP on surface tension at minimum bubble size was
pronounced (Figure 2C). TiO2 NSP at 100 μg/ml led to a
significant increase in surface tension from 1.1 ± 0.1 mN/
m up to 8.4 ± 3.1 mN/m. Further increase of particle dose
induced a strong surfactant dysfunction with γmin of 18.0
± 1.6 mN/m and 21.1 ± 0.4 mN/m after incubation withRespiratory Research 2009, 10:90 http://respiratory-research.com/content/10/1/90
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200 μg/ml and 500 μg/ml TiO2 NSP, respectively. TiO2
MSP led to a slight but non-significant increase in γmin
(Figure 2D).
Polystyrene NSP led to a slight increase in adsorption sur-
face tension from 45.7 ± 1.0 mN/ml up to 51.4 ± 0.9 mN/
ml which was only significant at a concentration of 500
μg/ml polystyrene NSP (Table 1). All other MSP did not
influence adsorption surface tension (Table 1). Surface
tension at minimum bubble size was also unaffected by
polystyrene MSP and quartz MSP (Table 1), while polysty-
rene NSP induced a strong surfactant dysfunction at min-
imum bubble size. Incubation with 500 μg/ml
polystyrene NSP during the cycling process led to a surface
tension of 17.5 ± 1.4 mN/m (Table 1).
Influence of Nanosized TiO2 Particles on Surfactant 
Ultrastructure
Natural porcine surfactant used in this study consisted
mostly of lamellar body-like forms. Unilamellar vesicles
were hardly present (Figure 3A and 3B). After addition of
100  μg/ml TiO2  NSP, lamellar body-like forms were
decreased in size and deformed (Figure 3C). In addition,
an increase in the amount of unilamellar vesicles
appeared (Figure 3C). Interestingly, small TiO2 NSP aggre-
gates accumulated between lamellae of the lamellar body-
like forms (Figure 3D). Rotation of the pure surfactant in
the absence of particles readily led to a conversion of
lamellar body-like forms to unilamellar vesicles (Figure
3E). Rotation in the presence of TiO2 NSP did not further
change subtype conversion (Figure 3F). However, large
Surface activity evaluated with the pulsating bubble surfactometer Figure 1
Surface activity evaluated with the pulsating bubble surfactometer. A) Adsorption surface tension (γads) after incuba-
tion with TiO2 nanosized particles (NSP) at a static bubble condition. B) Influence of TiO2 microsized particles (MSP) on γads C) 
Influence of TiO2 NSP on surface tension at minimal bubble size (γmin) during pulsation D) γmin after incubation with TiO2 MSP. 
Values are given as means of at least 4 experiments ± SEM. ** indicates p values < 0.01 compared with the control at 0 μg/ml 
particle concentration.
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TiO2 aggregates were found after rotation (Figure 3F).
These aggregates were larger in size than the TiO2 aggre-
gates in the non-rotated sample (Figure 3D).
Effect of inhaled particles on surfactant ultrastructure in 
rats
Semiquantitative analysis of intra-alveolar active (tubular
myelin and lamellar bodies) and inactive surfactant sub-
types (unilamellar vesicles) did not differ between both
groups. There were no signs of alveolar oedema or inflam-
mation.
Discussion
The present data show that nanosized particles, but not
microsized particles, induce a dysfunction of pulmonary
surfactant. Nanosized titanium dioxide as well as nano-
sized polystyrene particles at high concentrations can
induce a slight pulmonary surfactant dysfunction in vitro.
Interestingly, surface area cycling in vitro aggravated the
surfactant dysfunction induced by nanoparticles, both by
TiO2 NSP and by polystyrene NSP. In addition, biophysi-
cal alterations of pulmonary surfactant by TiO2 NSP were
accompanied by changes of the surfactant ultrastructure
indicating increased surfactant subtype conversion.
A direct interaction between particles and the surfactant
constituents is the most likely explanation for the
observed surfactant dysfunction. It is well known that
phospholipids bind to particles [10,14,23] and to TiO2
structures [24,25]. In this respect, surface area seems to be
the major determinant of the observed biophysical and
ultrastructural changes. Accordingly, particles with the
Table 1: Surface activity evaluated with the pulsating bubble surfactometer.
Polystyrene NSP Polystyrene MSP Quartz MSP
Direct effects - γ ads [mN/m]
0 μg/ml 29.2 ± 1.5 28.9 ± 2.7 25.9 ± 1.5
50 μg/ml 28.3 ± 1.4 28.3 ± 2.2 25.0 ± 1.6
100 μg/ml 30.8 ± 2.2 28.6 ± 2.3 25.0 ± 2.0
200 μg/ml 32.4 ± 2.1 30.1 ± 3.0 26.3 ± 2.9
500 μg/ml 34.1 ± 2.2** 28.3 ± 2.3 25.2 ± 1.5
Direct effects - γ min [mN/m]
0 μg/ml 4.0 ± 0.9 2.4 ± 1.2 4.9 ± 0.5
50 μg/ml 5.1 ± 0.9 2.2 ± 0.9 4.1 ± 0.9
100 μg/ml 4.0 ± 1.0 2.8 ± 1.8 4.6 ± 0.8
200 μg/ml 4.7 ± 1.1 3.1 ± 1.3 4.1 ± 0.9
500 μg/ml 6.8 ± 1.2** 3.0 ± 1.5 5.0 ± 0.8
Surface area cycling - γ ads [mN/m]
Control 27.1 ± 1.5 27.4 ± 2.7 28.1 ± 0.8
0 μg/ml 45.7 ± 1.0 46.4 ± 1.3 43.7 ± 0.8
50 μg/ml 42.4 ± 2.2 43.7 ± 2.2 47.1 ± 0.9
100 μg/ml 47.1 ± 1.3 43.1 ± 0.8 45.8 ± 2.8
200 μg/ml 44.6 ± 2.1 45.3 ± 2.3 45.4 ± 3.1
500 μg/ml 51.4 ± 0.9* 42.7 ± 1.7 48.4 ± 1.5
Surface area cycling - γ min [mN/m]
Control 1.1 ± 0.2 1.1 ± 0.2 1.2 ± 0.4
0 μg/ml 1.2 ± 0.2 1.1 ± 0.2 1.7 ± 0.4
50 μg/ml 2.1 ± 0.4 1.1 ± 0.4 0.9 ± 0.3
100 μg/ml 1.5 ± 0.5 1.2 ± 0.2 2.1 ± 0.9
200 μg/ml 6.3 ± 2.8 1.8 ± 0.5 2.8 ± 0.7
500 μg/ml 17.5 ± 1.4*** 1.9 ± 0.5 1.0 ± 0.3
Direct effects were measured immediately after addition of particles, effects after surface area cycling were measured following 8 hour rotation at 
0.43 Hz with or without particles. Adsorption surface tension (γads) was obtained from the value of a static bubble. Surface tension at minimal 
bubble size (γmin) was recorded during pulsation. Values are given as means ± SEM of at least 4 experiments. * indicates p values < 0.05; ** indicates 
p values < 0.01; *** indicates p values < 0.001; all compared with the control without particles (0 μg/ml). In case of surface area cycling, the 0 μg/ml 
control was rotated for 8 hours at 0.43 Hz. NSP - nanosized particles; MSP - microsized particles.Respiratory Research 2009, 10:90 http://respiratory-research.com/content/10/1/90
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highest surface area - TiO2 NSP and also reference polysty-
rene NSP - induced the most prominent alterations.
Microsized particles with a relatively low surface area did
not induce a surfactant dysfunction in our study.
In separate experiments, we compared equal surface areas
by testing very high microparticle mass concentrations.
With concentrations of ~10 mg/ml TiO2 MSP and quartz
MSP, we observed a strong surfactant dysfunction. How-
ever, the experimental conditions were limited because
microsized particles at this very high concentration aggre-
gated and rapidly sedimented to the bottom of the test
capillary. By this segregation, the phospholipid concentra-
tion was not stable which limits the comparison of NSP
and MSP at similar surface areas.
Bakshi and coworkers demonstrated a potent pulmonary
surfactant dysfunction at low concentrations of ~2 μg/ml
gold nanoparticles [14]. In contrast, much higher concen-
trations of TiO2 NSP were required to induce an increase
of surface tension in our experiments. In addition, the
degree of surfactant dysfunction was less with TiO2 NSP in
our study compared to the gold nanoparticles used by
Bakshi et al. Differences in 1) the measuring system, 2) the
surfactant preparation and concentration, or 3) the nano-
particles themselves might account for the discrepancy.
Surface activity evaluated with the pulsating bubble surfactometer following 8 hour rotation at 0.43 Hz Figure 2
Surface activity evaluated with the pulsating bubble surfactometer following 8 hour rotation at 0.43 Hz. A) 
Influence of TiO2 NSP on adsorption surface tension (γads) at a static bubble condition. B) Influence of TiO2 MSP on γads  C) 
Influence of TiO2 NSP on surface tension at minimal bubble size (γmin) during pulsation D) TiO2 MSP effect on γmin. Values are 
given as means ± SEM of at least 4 experiments. ** indicates p values < 0.01; *** indicates p values < 0.001; both compared with 
the rotated 0 μg/ml particle concentration (grey columns). CO/white columns - control surfactant which was placed for 8 
hours in an incubator without rotation.
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Representative transmission electron microscope pictures of the surfactant ultrastructure Figure 3
Representative transmission electron microscope pictures of the surfactant ultrastructure. A) and B) untreated 
control surfactant. C) and D) porcine surfactant after addition of 100 μg/ml TiO2 nanosized particles. Red circles show small 
particle aggregates. E) Control surfactant after 8 hours rotation at 0.43 Hz and 37°C. F) Surfactant after 8 hours rotation at 
0.43 Hz and 37°C in the presence of 100 μg/ml TiO2 nanosized particles. Black arrows show large particle aggregates; lbl - 
lamellar body like forms; ulv - unilamellar vesicles.Respiratory Research 2009, 10:90 http://respiratory-research.com/content/10/1/90
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Both, the pulsating bubble surfactometer (PBS) and the
captive bubble surfactometer (CPS) are able to evaluate
low surface tensions [26] while the CPS is regarded to
yield even lower surface tensions [27] which makes differ-
ences in the device an unlikely explanation. Regarding
surfactant preparation and concentration, we used Curo-
surf®, a natural surfactant derived from minced porcine
lungs [28] while a semisynthetic surfactant composed of
two phospholipids plus SP-B was used by Bakshi. It is
unlikely that differences in the surfactants are solely
responsible for the different effects seen with gold nano-
particles and TiO2 NSP. Both surfactants have been dem-
onstrated to have excellent surface activity and to achieve
very low surface tensions under compression at the con-
centrations used. The most likely explanation for the
potent dysfunction in the study by Bakshi seems related to
the material properties (size/surface) of the gold nanopar-
ticles. Since the gold NSP had citrate groups on their sur-
face, aggregation is mostly avoided [29]. In contrast, pure
TiO2 nanoparticles highly aggregate. Although the surface
area is not known for the gold NSP from Bakshis study, it
is likely that the surface area per mass unit is higher for the
citrate coated gold NSP than for the TiO2 NSP. This could
explain the more potent induction of surfactant dysfunc-
tion by gold NSP compared to TiO2 NSP because sur-
factant components could be bound to the large gold
nanoparticle surface area making them unavailable for
lowering surface tension at the air-liquid interface.
In an attempt of direct comparison between TiO2 NSP and
the gold nanoparticles by Bakshi (~15 nm), we tested
commercially available gold NSP with citrate coating (5
nm) in single experiments. Interestingly, at equal mass the
surfactant dysfunction by gold NSP was stronger com-
pared with TiO2 NSP. However, the dysfunction was less
compared with data from Bakshi et al., but this discrep-
ancy can be accounted to differences in surface area of the
gold NSP or the surfactant preparations used in both stud-
ies.
The in vivo conversion of surface active LA to inferior SA
can be simulated in vitro by surface area cycling [16]. By
this technique, the impact of meconium, serum proteins,
or surfactant proteins during the surfactant conversion
process have been studied [19,30-32]. We assessed the
effect of TiO2 NSP on the conversion process. Importantly,
a dose-dependent increase in surface tension was
obtained. Remarkably, this effect was much stronger than
the direct biophysical effect of TiO2 NSP without cycling.
TEM pictures demonstrated that the occurrence of unila-
mellar vesicles was independent from NSP presence. Pos-
sibly, binding of NSP to SP-B and subsequent loss of SP-B
from the air-liquid-interface could explain the loss of sur-
face activity following surface area cycling in the presence
of NSP. In vivo, SP-B becomes cleaved by a serine active
carboxylesterase called convertase [33-35]. However,
Curosurf® is prepared by chlorofom extraction and hence
does not contain convertase [20]. Therefore, intact SP-B
should be present in Curosurf® following surface area
cycling. We speculate that free SP-B could interact with
TiO2 NSP which in turn becomes depleted leading to dis-
turbed surfactant function. High ability of SP-B to bind to
surfaces during surface area cycling was shown before
when binding of SP-B to tube walls was investigated dur-
ing surface area cycling [18]. Unfortunately, we were not
able to provide direct evidence of binding of SP-B to TiO2
NSP by TEM due to methodological limitations.
Admittedly, inhaled particles act directly on the surfactant
layer at the air-liquid interface and not primarily through
the subphase as in our in vitro experiments. However, after
deposition at the air-liquid interface the particles subse-
quently become dissolved in the epithelial lining layer
and interfere with the dynamic process of phospholipid
arrangement at the interface. Therefore, the assay system
with the pulsating bubble surfactometer is at least capable
to demonstrate differential effects of nanoparticles versus
microparticles in phospholipid suspensions when parti-
cles interfere with the formation of the surfactant layer
from the hypophase. It is very well conceivable that the
initial effect of particles might even be greater when they
are reaching the interface directly.
Although we have demonstrated that TiO2 NSP elicited
biophysical and structural changes of surfactant in vitro,
the in vivo relevance has to be scrutinized because the par-
ticle concentrations that we found effective in vitro can
hardly occur in vivo. With the human alveolar surface area
of ~100 m2 and assuming an average thickness of the alve-
olar lining fluid of approximately 200 nm [36], the
amount of alveolar lining fluid can be assessed as ~20 ml.
In accordance, the epithelial lining fluid has been sug-
gested to be 6 ml/L total lung capacity, resulting in 40 ml
in man [37]. With the assumption of a particle concentra-
tion of 100 μg/m3, which can occur in polluted inner cit-
ies, and an alveolar deposition rate as high as 50%, the
amount of particles deposited per day would be ~360 μg.
At steady state, this would result in a concentration of ~10
μg nanoparticles per ml alveolar lining fluid. This particle
concentration is far below what has been demonstrated to
cause a surfactant dysfunction in our study. In addition,
clearance of particles and secretion of newly synthesized
surfactant would further improve this particle/surfactant
ratio and consequently question whether nanoparticles
can cause a surfactant alteration under these conditions in
vivo. This view is supported by our experimental evidence
in rats. Following inhalation of TiO2 particles that were
aerosolized and adjusted to result in the highest techni-
cally possible alveolar deposition of 60 μg particles per
animal, surfactant ultrastructure was found unaffected inRespiratory Research 2009, 10:90 http://respiratory-research.com/content/10/1/90
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vivo. Assuming an alveolar lining fluid in rats of approxi-
mately 70 μL [36], the in vivo particle concentration in the
epithelial lining fluid would have been approximately
53.5 μg/mL (normalized to 1.5 mg/ml phospholipids and
assuming static conditions). Noteworthy, the local con-
centration at the air-liquid interface was probably much
higher suggesting that no changes of surfactant ultrastruc-
ture occur in vivo under acute maximal TiO2 particle expo-
sure.
Although these considerations suggest that the impact of
TiO2 NSP on surfactant function in the human lung is
highly unlikely to cause adverse effects in healthy individ-
uals, in diseased subjects, however, additive effects of NSP
on pulmonary surfactant function and ultrastructure have
to be taken into account. For example, it has been demon-
strated that a pulmonary surfactant dysfunction can be
found in various airway diseases like asthma [38], cystic
fibrosis [39], or after lung transplantation [40]. In partic-
ular, leakage of plasma proteins into the airway lumen is
known to induce a surfactant dysfunction [41,42]. Impor-
tantly, NSP can induce [43-45] or enhance [46,47] pul-
monary inflammation which is accompanied by protein
leakage. This in turn could lead to a surfactant dysfunction
in vivo. Moreover, NSP are able to induce oxidative stress
and lipid peroxidation [48-50]. Oxidative stress with lipid
peroxidation can induce an increase in surface tension
[51,52]. In addition, NSPs emitted by engines are contam-
inated with alkanes and sulfates [53] and it is known, that
eicosane, a specific n-alkane constituent of diesel exhaust
NSPs, can affect the biophysical surfactant function [54].
Therefore, nanoparticles might amplify alterations of the
pulmonary surfactant system, particularly under predis-
posed conditions of airway inflammation.
Conclusion
Taken together, TiO2 NSP induce biophysical and struc-
tural alterations of pulmonary surfactant in vitro. Under
dynamic conditions of surface area cycling, this interfer-
ing impact is aggravated. Although our data do not sug-
gest that inhalation of nanoparticles cause a significant
disturbance of the pulmonary surfactant system in vivo,
nanoparticles might be detrimental in patients with preex-
isting airway disease.
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